ClinicalTrials.gg
RecruitingNCT06642896OSMOPUPILLOUpdated Apr 2, 2025

Quantitative Pupillometry in Brain Injury Children : Variation After Osmotherapy

An observational study in Children Brain Injury, sponsored by University Hospital, Grenoble. Recruiting at 2 sites in France. Open to participants aged 1 Month to 17 Years. Per ClinicalTrials.gov, last updated 2025-04-02.

Sponsored by University Hospital, Grenoble · Observational

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
90
Ages
1 Month to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Craniocerebral Trauma with a site in France — 6 open to participants now, 6 under way, none of them phase 3. Craniocerebral Trauma · France.

Planned enrollment
14th of 21
90 · median 130
Started
2024
with 1 other
Observational
21 of 36
4 open now
Registered
31st of 36
by date

Among the 36 studies in Craniocerebral Trauma with a site in France, this one is the 14th largest by planned enrollment of the 21 observational ones that give a count, is one of 2 that started in 2024, is one of 21 observational ones, and was the 31st registered.

Craniocerebral Trauma

253 studies on the registry are indexed under Craniocerebral Trauma; 45 are open to participants now.

Browse Craniocerebral Trauma studies →

Open to participants now

6 of the 36 studies in Craniocerebral Trauma with a site in France are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 25 Craniocerebral Trauma studies recruiting now, 8 (32%) set no upper age limit and 14 (56%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.

This study: 1 Month to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Craniocerebral Trauma with a site in France, or all of them as a file.
02

Study summary

Intracranial hypertension (ICH) is a common and serious complication in children admitted to pediatric intensive care units. It is primarily caused by traumatic brain injury but can also result from brain malformations, brain tumors, or neuro-meningeal infections. Rapid identification of ICH in acute settings is crucial to ensure prompt management and mitigate potential consequences, such as severe neurological sequelae or death.

The assessment of the pupillary light reflex is one of the key clinical parameters used to identify ICH in children with neurological injuries. This clinical sign is correlated with neurological prognosis. During an episode of ICH, regardless of the underlying cause, the oculomotor nerve becomes compressed between the midbrain and the temporal lobe, leading to anisocoria (unequal pupil sizes) and loss of pupillary reactivity. Other factors, such as episodes of ischemia or hypoperfusion in the midbrain, can also contribute to decreased pupillary reactivity.

Read the detailed description

Traditionally, the pupillary light reflex is assessed using a simple light source, with subjective evaluation by a healthcare professional. However, this method has significant inter- and intra-individual variability. Quantitative pupillometry offers a more objective and reproducible way to evaluate pupillary reactivity. In adults, some parameters are well-known indicators of ICH, such as a constriction velocity of less than 0.6 mm/sec and a constriction percentage below 10%. The constriction percentage can be simplified with the Neurological Pupil index (NPI), which ranges from 0 to 5. An NPI of 4 or 5 is considered to indicate good pupillary reactivity. The two quantitative pupillometers currently on the market (Neurolight, Neuroptics) appear to provide similar data for most variables assessed. However, there are few studies evaluating this tool in pediatric patients with neurological injuries.

One study on quantitative pupillometry found that children with neurological injuries and an intracranial pressure (ICP) above 20 mmHg had significantly lower pupillary reactivity, NPI, constriction percentage, and dilation and constriction velocities compared to children without ICH.

Osmotherapy is a commonly used pharmacological intervention in pediatrics to lower intracranial pressure and improve cerebral perfusion pressure. Based on the work of Freeman et al., we hypothesize that the pupillary constriction percentage improves after osmotherapy in children with neurological injuries.

03

Conditions studied

  • Children Brain Injury

Browse trials for

Keywords

  • brain lesion
  • pupillometry
  • assess variation in the percentage of pupillary constriction
  • children
  • severe head trauma
04

Who can participate

Ages eligible
1 Month to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

children aged 1 month to 17 years with brain lesion receiving osmotherapy

Eligibility criteria

Inclusion Criteria:

  • Hospitalized in a pediatric intensive care unit or neurosurgical intensive care unit
  • Inclusion within 24 hours of ICU admission
  • with clinically suspected HTIC (disorders of consciousness with transcranial Doppler abnormality, symptoms of involvement, poor cerebral perfusion pressure) for which osmotherapy is prescribed

Exclusion Criteria:

  • Presence of eye damage (or antecedent)
  • Refusal by parents and/or child Opposition by child or parental guardians.
  • Persons not affiliated to the social security system.
  • Protected persons (under guardianship, curatorship, pregnant or breast- feeding women, persons deprived of their liberty, persons not subject to a psychiatric measure
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
90 participants (estimated)
Target follow-up
10 Days
Patient registry
Yes

Groups and cohorts

  • severe head trauma in children with osmotherapy treatment

    Admission to the pediatric intensive care or neurosurgical intensive care unit, pupillometry measurement before and after osmotherapy treatment

    Device: pupillometer

  • pupillometry measurement in non-cerebral pediatric patients

    feasibility of pupillometry in children for different age groups and obtain baseline values for non-neurologically sedated children in 4 age groups from 0 to 17 years of age in intensive care and the operating room

    Device: pupillometer

Interventions

  • Devicepupillometer

    describe the feasibility of pupillometry measurements in sedated but non-cerebrosed children in intensive care and the operating room

  • Devicepupillometer

    Pupillometry measurements at 5 and 25 minutes for children treated with osmotherapy, followed by measurements twice a day during hospitalization in the intensive care unit

06

What researchers measure

Primary outcomes

  1. to describe and evaluate the variation in the percentage of pupillary constriction (CON) before, and after osmotherapy in neuro-injured children.

    Delta (in percentage difference, and in delta of values) of the constriction (CON) between the last available measurement before the osmotherapy was started, and the measurement 5 minutes after the end (at 25 minutes after the start of the osmotherapy). For each child, the eye with the lowest constriction (CON) value before osmotherapy will be considered.

    Time frame: at 10 days

  2. Describe the feasibility of pupillometry in children for different age groups, and obtain baseline values for the sedated, non-neurosed child.

    Success rate in obtaining pupillometric values for different age groups. Pupillometric values: QPI (quantitative pupillometry index) in intensive care and the operating room

    Time frame: at 1 minute and 25 minutes

  3. Describe the feasibility of pupillometry in children for different age groups, and obtain baseline values for the sedated, non-neurosed child.

    Success rate in obtaining pupillometric values for different age groups. Pupillometric values: latency (LAT) in intensive care and the operating room

    Time frame: at 1 minute and 25 minutes

  4. Describe the feasibility of pupillometry in children for different age groups, and obtain baseline values for the sedated, non-neurosed child.

    Success rate in obtaining pupillometric values for different age groups. Pupillometric values: constriction velocity (ACV) and dilatation velocity (ADV) in mm/sec in intensive care and the operating room

    Time frame: at 1 minute and 25 minutes

  5. Describe the feasibility of pupillometry in children for different age groups, and obtain baseline values for the sedated, non-neurosed child.

    Success rate in obtaining pupillometric values for different age groups. Pupillometric values: minimum (MIN) and maximum (MAX) pupillary diameter in mm in intensive care and the operating room

    Time frame: at 1 minute and 25 minutes

Secondary outcomes

  1. In the age subgroup of children with an intracranial pressure (ICP) sensor (pathological if ICP more than 20mmHg), evaluate the relationship between intracranial pressure and the various pupillometry values (LAT).

    Assessing the association between latency in sec (LAT) and ICP (mmhg)

    Time frame: per 12h during 10 days

  2. In the age subgroup of children with an intracranial pressure (ICP) sensor (pathological if ICP more than 20mmHg), evaluate the relationship between intracranial pressure and the various pupillometry values (QPI).

    Assessing the association between measurements of pupillometry, QPI, quantitative pupillometry index

    Time frame: per 12h during 10 days

  3. In the age subgroup of children with an intracranial pressure (ICP) sensor (pathological if ICP more than 20mmHg), evaluate the relationship between intracranial pressure and the various pupillometry values.(CON)

    Assessing the association between measurements of pupillometry, percentage of constriction (CON) and ICP.

    Time frame: per 12h during 10 days

  4. In the age subgroup of children with an intracranial pressure (ICP) sensor (pathological if more than 20mmHg), evaluate the relationship between intracranial pressure and the various pupillometry values (Max; Min)

    To asses association between intracranial pressure and minimum et maximum pupillary diameter (in mm).

    Time frame: per 12h during 10 days

  5. In the age subgroup of children with an intracranial pressure (ICP) sensor (pathological if more than 20mmHg), evaluate the relationship between intracranial pressure and the various pupillometry values. (ACV and ADV)

    To asses association between ICP and pupillometry values : constriction velocity (ACV) and dilatation velocity (ADV) in mm.sec

    Time frame: per 12h during 10 days

  6. Comparison of pupillometry values between neuro-sedated and non-neuro-sedated children, adjusting for age

    measurement of pupillometric parameters : latence (in sec)

    Time frame: at 1 and 25 minutes

  7. Comparison of pupillometry values between neuro-sedated and non-neuro-sedated children, adjusting for age.

    measurement of pupillometric parameters : quantitative pupillometry index, pupil constriction

    Time frame: at 1 and 25 minutes

  8. Comparison of pupillometry values between neuro-sedated and non-neuro-sedated children, adjusting for age.

    measurement of pupillometric parameters : Minimum and maximum pupillary diameter (in mm)

    Time frame: at 1 and 25 minutes

  9. Comparison of pupillometry values between neuro-sedated and non-neuro-sedated children, adjusting for age.

    measurement of pupillometric parameters constriction velocity (ACV), dilatation velocity (ADV) in mm/sec

    Time frame: at 1 and 25 min

  10. Describe the evolution of different pupillometry measurements before and after osmotherapy

    Measure of pupillometry: CON and QPI after osmotherapy administration

    Time frame: at 15 , 25, 35, 45, 60, 120, 240 minutes

  11. Describe the evolution of different pupillometry measurements before and after osmotherapy

    Measure of pupillometry : constriction velocity (ACV), dilatation velocity (ADV) in mm/sec

    Time frame: [Time Frame: at 15 , 25, 35, 45, 60, 120, 240 minutes]

  12. Describe the evolution of different pupillometry measurements before and after osmotherapy

    Measure of pupillometry: latence (in mm)

    Time frame: [Time Frame: at 15 , 25, 35, 45, 60, 120, 240 minutes]

  13. Describe the evolution of different pupillometry measurements before and after osmotherapy

    Measure of pupillometry: Min and max pupillary diameter in mm.

    Time frame: at 15 , 25, 35, 45, 60, 120, 240 minutes

  14. Assessing the relationship between transcranial Doppler (CTD) results: pulsatility index (PI) and diastolic velocity (Vd)

    Repeated pupillometry measurements : (LAT) latence in sec and transcranial doppler

    Time frame: 2 times a day for 10 days or on discharge from hospital

  15. Assessing the relationship between transcranial Doppler (CTD) results: pulsatility index (PI) and diastolic velocity (Vd)

    Repeated pupillometry measurements QPI and CON and transcranial doppler

    Time frame: 2 times a day for 10 days or on discharge from hospital

  16. Assessing the relationship between transcranial Doppler (CTD) results: pulsatility index (PI) and diastolic velocity (Vd)

    Repeated pupillometry measurements (Maximum and minimum pupillary diameter in mm) and transcranial doppler

    Time frame: 2 times a day for 10 days or on discharge from hospital

  17. Assessing the relationship between transcranial Doppler (CTD) results: pulsatility index (PI) and diastolic velocity (Vd)

    Repeated pupillometry measurements (constriction velocity (ACV) and dilatation velocity (ADV) in mm.sec) and transcranial doppler

    Time frame: 2 times a day for 10 days or on discharge from hospital

07

Study locations

1 of 2 sites recruiting
08

References and documents

Publications

  • Winston M, Zhou A, Rand CM, Dunne EC, Warner JJ, Volpe LJ, Pigneri BA, Simon D, Bielawiec T, Gordon SC, Vitez SF, Charnay A, Joza S, Kelly K, Panicker C, Rizvydeen S, Niewijk G, Coleman C, Scher BJ, Reed DW, Hockney SM, Buniao G, Stewart T, Trojanowski L, Brogadir C, Price M, Kenny AS, Bradley A, Volpe NJ, Weese-Mayer DE. Pupillometry measures of autonomic nervous system regulation with advancing age in a healthy pediatric cohort. Clin Auton Res. 2020 Feb;30(1):43-51. doi: 10.1007/s10286-019-00639-3. Epub 2019 Sep 25. PubMed 31555934 ↗
  • Boev AN, Fountas KN, Karampelas I, Boev C, Machinis TG, Feltes C, Okosun I, Dimopoulos V, Troup C. Quantitative pupillometry: normative data in healthy pediatric volunteers. J Neurosurg. 2005 Dec;103(6 Suppl):496-500. doi: 10.3171/ped.2005.103.6.0496. PubMed 16383247 ↗
  • Rouche O, Wolak-Thierry A, Destoop Q, Milloncourt L, Floch T, Raclot P, Jolly D, Cousson J. Evaluation of the depth of sedation in an intensive care unit based on the photo motor reflex variations measured by video pupillometry. Ann Intensive Care. 2013 Feb 22;3(1):5. doi: 10.1186/2110-5820-3-5. PubMed 23433043 ↗
  • Freeman AD, McCracken CE, Stockwell JA. Automated Pupillary Measurements Inversely Correlate With Increased Intracranial Pressure in Pediatric Patients With Acute Brain Injury or Encephalopathy. Pediatr Crit Care Med. 2020 Aug;21(8):753-759. doi: 10.1097/PCC.0000000000002327. PubMed 32195898 ↗
  • Robba C, Moro Salihovic B, Pozzebon S, Creteur J, Oddo M, Vincent JL, Taccone FS. Comparison of 2 Automated Pupillometry Devices in Critically III Patients. J Neurosurg Anesthesiol. 2020 Oct;32(4):323-329. doi: 10.1097/ANA.0000000000000604. PubMed 31033624 ↗
  • Bower MM, Sweidan AJ, Xu JC, Stern-Neze S, Yu W, Groysman LI. Quantitative Pupillometry in the Intensive Care Unit. J Intensive Care Med. 2021 Apr;36(4):383-391. doi: 10.1177/0885066619881124. Epub 2019 Oct 10. PubMed 31601157 ↗
  • Ritter AM, Muizelaar JP, Barnes T, Choi S, Fatouros P, Ward J, Bullock MR. Brain stem blood flow, pupillary response, and outcome in patients with severe head injuries. Neurosurgery. 1999 May;44(5):941-8. doi: 10.1097/00006123-199905000-00005. PubMed 10232526 ↗
  • Manley GT, Larson MD. Infrared pupillometry during uncal herniation. J Neurosurg Anesthesiol. 2002 Jul;14(3):223-8. doi: 10.1097/00008506-200207000-00009. PubMed 12172296 ↗
  • Rameshkumar R, Bansal A, Singhi S, Singhi P, Jayashree M. Randomized Clinical Trial of 20% Mannitol Versus 3% Hypertonic Saline in Children With Raised Intracranial Pressure Due to Acute CNS Infections. Pediatr Crit Care Med. 2020 Dec;21(12):1071-1080. doi: 10.1097/PCC.0000000000002557. PubMed 33003179 ↗
  • Piper BJ, Harrigan PW. Hypertonic saline in paediatric traumatic brain injury: a review of nine years' experience with 23.4% hypertonic saline as standard hyperosmolar therapy. Anaesth Intensive Care. 2015 Mar;43(2):204-10. doi: 10.1177/0310057X1504300210. PubMed 25735686 ↗
  • Kochanek PM, Adelson PD, Rosario BL, Hutchison J, Miller Ferguson N, Ferrazzano P, O'Brien N, Beca J, Sarnaik A, LaRovere K, Bennett TD, Deep A, Gupta D, Willyerd FA, Gao S, Wisniewski SR, Bell MJ; ADAPT Investigators. Comparison of Intracranial Pressure Measurements Before and After Hypertonic Saline or Mannitol Treatment in Children With Severe Traumatic Brain Injury. JAMA Netw Open. 2022 Mar 1;5(3):e220891. doi: 10.1001/jamanetworkopen.2022.0891. PubMed 35267036 ↗
  • Rallis D, Poulos P, Kazantzi M, Chalkias A, Kalampalikis P. Effectiveness of 7.5% hypertonic saline in children with severe traumatic brain injury. J Crit Care. 2017 Apr;38:52-56. doi: 10.1016/j.jcrc.2016.10.014. Epub 2016 Oct 21. PubMed 27838440 ↗
  • Melo JR, Di Rocco F, Blanot S, Cuttaree H, Sainte-Rose C, Oliveira-Filho J, Zerah M, Meyer PG. Transcranial Doppler can predict intracranial hypertension in children with severe traumatic brain injuries. Childs Nerv Syst. 2011 Jun;27(6):979-84. doi: 10.1007/s00381-010-1367-8. Epub 2011 Jan 5. PubMed 21207041 ↗

Individual participant data

Plan to share: No — This is an observational study, which does not modify the management of children with brain lesions, nor does it generate additional therapies.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Oct 2027, 35 months after the start.

Of 43 non-industry observational studies under Craniocerebral Trauma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's planned 35 months is close to that.

Counting every sponsor, half of 43 studies reached it within 32 months; a quarter within 15 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2024
First posted
Oct 15, 2024
StartActual
Nov 11, 2024
Primary completionEst.
Oct 31, 2027
CompletionEst.
Apr 1, 2028
Last update
Apr 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06642896
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Nov 11, 2024
Primary completion
Oct 31, 2027 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
Apr 2, 2025

Study contacts

Sarah SS SINTZEL STRIPPPOLI, Doctor
Contact
ssintzelstrippoli@chu-grenoble.fr
0476766729 ext. +33
Angélina AP POLLET, RESEARCH NURSE
Contact
apollet@chu-grenoble.fr
0476766729 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion